NCT01412801View on ClinicalTrials.gov

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Streptococcal InfectionsGram-Positive Bacterial InfectionsBacterial Infections
Interventions
BIOLOGICAL

Group B streptococcus vaccine

Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.

Trial Locations (2)

2013

Chris Hani Baragwanath Hospital, Bertsham

Unknown

Limbe Health Center, Blantyre

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY